Abstract
Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor for glutamate, though its effects are mediated by interaction with many others receptors. It has been introduced in clinical use since 1960s but today it is not largely employed as a general anaesthetic for its undesired psychic effects (emergence reactions) occurring in approximately 12% of patients. In the last decade, there has been a renewed interest in the use of subanaesthetic doses of ketamine for the treatment of acute and chronic pain. In the late 1990s, multiple prospective, randomised, controlled study has shown the efficacy of low dose of ketamine for postoperative pain relief, for analgesia during regional or local anaesthesia, and for opioid-sparing effect. At present, non-definitive conclusion can be drawn. More data are needed to define the possible long term effects and the clinical goal of ketamine use.
Current Drug Targets
Title: Ketamine: New Indications for an Old Drug
Volume: 6 Issue: 7
Author(s): M. G. Annetta, D. Iemma, C. Garisto, C. Tafani and R. Proietti
Affiliation:
Keywords: ketamine, analgesia, opioids
Abstract: Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor for glutamate, though its effects are mediated by interaction with many others receptors. It has been introduced in clinical use since 1960s but today it is not largely employed as a general anaesthetic for its undesired psychic effects (emergence reactions) occurring in approximately 12% of patients. In the last decade, there has been a renewed interest in the use of subanaesthetic doses of ketamine for the treatment of acute and chronic pain. In the late 1990s, multiple prospective, randomised, controlled study has shown the efficacy of low dose of ketamine for postoperative pain relief, for analgesia during regional or local anaesthesia, and for opioid-sparing effect. At present, non-definitive conclusion can be drawn. More data are needed to define the possible long term effects and the clinical goal of ketamine use.
Export Options
About this article
Cite this article as:
Annetta G. M., Iemma D., Garisto C., Tafani C. and Proietti R., Ketamine: New Indications for an Old Drug, Current Drug Targets 2005; 6 (7) . https://dx.doi.org/10.2174/138945005774574533
DOI https://dx.doi.org/10.2174/138945005774574533 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Controlled Somatic and Germline Copy Number Variation in the Mouse Model
Current Genomics Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry Computational Methods Dedicated to Neurological Disorder Detection through Epistasis Analysis: A Review
Current Chinese Engineering Science Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy Serotonin<sub>2c</sub> Receptor Constitutive Activity: In vivo Direct and Indirect Evidence and Functional Significance
Central Nervous System Agents in Medicinal Chemistry Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry Recent Developments on the Use of Nanomaterials for the Treatment of Epilepsy
Mini-Reviews in Medicinal Chemistry Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs
Current Topics in Medicinal Chemistry Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology Current Development in Encapsulated Cell Therapy for Degenerative Retinopathies
Current Tissue Engineering (Discontinued) Commentary: Gut Microbiota and Brain Function: A New Target for Brain Diseases?
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of Neurogenesis for Prevention and Recovery from Alzheimers Disease: Allopregnanolone as a Proof of Concept Neurogenic Agent
Current Alzheimer Research Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Current Signal Transduction Therapy A Case of Topiramate-Induced Epistaxis
Current Drug Safety α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies